Free Trial

Deciphera Pharmaceuticals (DCPH) Competitors

$25.51
0.00 (0.00%)
(As of 05:27 PM ET)

DCPH vs. GERN, VERA, RYTM, AMRX, INDV, AMPH, ARVN, RCKT, BHC, and ZLAB

Should you be buying Deciphera Pharmaceuticals stock or one of its competitors? The main competitors of Deciphera Pharmaceuticals include Geron (GERN), Vera Therapeutics (VERA), Rhythm Pharmaceuticals (RYTM), Amneal Pharmaceuticals (AMRX), Indivior (INDV), Amphastar Pharmaceuticals (AMPH), Arvinas (ARVN), Rocket Pharmaceuticals (RCKT), Bausch Health Companies (BHC), and Zai Lab (ZLAB). These companies are all part of the "pharmaceutical preparations" industry.

Deciphera Pharmaceuticals vs.

Geron (NASDAQ:GERN) and Deciphera Pharmaceuticals (NASDAQ:DCPH) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, dividends, analyst recommendations, valuation, profitability, institutional ownership, risk, community ranking and earnings.

73.7% of Geron shares are held by institutional investors. Comparatively, 71.0% of Deciphera Pharmaceuticals shares are held by institutional investors. 3.0% of Geron shares are held by company insiders. Comparatively, 4.7% of Deciphera Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Deciphera Pharmaceuticals has a net margin of -108.86% compared to Deciphera Pharmaceuticals' net margin of -38,730.00%. Geron's return on equity of -52.42% beat Deciphera Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Geron-38,730.00% -68.16% -47.26%
Deciphera Pharmaceuticals -108.86%-52.42%-40.05%

Geron has a beta of 0.55, suggesting that its share price is 45% less volatile than the S&P 500. Comparatively, Deciphera Pharmaceuticals has a beta of 0.2, suggesting that its share price is 80% less volatile than the S&P 500.

Geron received 159 more outperform votes than Deciphera Pharmaceuticals when rated by MarketBeat users. Likewise, 69.52% of users gave Geron an outperform vote while only 64.91% of users gave Deciphera Pharmaceuticals an outperform vote.

CompanyUnderperformOutperform
GeronOutperform Votes
479
69.52%
Underperform Votes
210
30.48%
Deciphera PharmaceuticalsOutperform Votes
320
64.91%
Underperform Votes
173
35.09%

Geron currently has a consensus target price of $6.10, indicating a potential upside of 87.12%. Deciphera Pharmaceuticals has a consensus target price of $24.17, indicating a potential downside of 5.28%. Given Deciphera Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts clearly believe Geron is more favorable than Deciphera Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Geron
0 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.80
Deciphera Pharmaceuticals
0 Sell rating(s)
7 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.30

Geron has higher earnings, but lower revenue than Deciphera Pharmaceuticals. Deciphera Pharmaceuticals is trading at a lower price-to-earnings ratio than Geron, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Geron$240K8,056.68-$184.13M-$0.35-9.31
Deciphera Pharmaceuticals$174.91M12.62-$194.94M-$2.21-11.55

In the previous week, Deciphera Pharmaceuticals had 2 more articles in the media than Geron. MarketBeat recorded 8 mentions for Deciphera Pharmaceuticals and 6 mentions for Geron. Deciphera Pharmaceuticals' average media sentiment score of 1.35 beat Geron's score of 1.24 indicating that Geron is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Geron
2 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Deciphera Pharmaceuticals
3 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Geron beats Deciphera Pharmaceuticals on 12 of the 18 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DCPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

DCPH vs. The Competition

MetricDeciphera PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$2.21B$6.64B$4.96B$8.05B
Dividend YieldN/A2.77%2.80%3.97%
P/E Ratio-11.5512.15139.1615.77
Price / Sales12.62247.342,450.0972.66
Price / CashN/A33.0734.6931.30
Price / Book6.995.815.474.57
Net Income-$194.94M$137.94M$104.51M$213.29M
7 Day Performance0.20%-1.50%-0.92%-1.13%
1 Month Performance0.99%1.08%2.20%2.17%
1 Year Performance85.13%-3.34%4.92%6.99%

Deciphera Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
GERN
Geron
3.8915 of 5 stars
$3.70
-0.8%
$6.10
+64.9%
+3.1%$2.19B$240,000.00-10.57141Positive News
VERA
Vera Therapeutics
0.5957 of 5 stars
$39.76
-3.0%
$36.71
-7.7%
+387.9%$2.17BN/A-19.4051News Coverage
Gap Down
RYTM
Rhythm Pharmaceuticals
3.4431 of 5 stars
$38.01
-2.4%
$54.33
+42.9%
+121.9%$2.32B$77.43M-8.21226
AMRX
Amneal Pharmaceuticals
0.9366 of 5 stars
$6.69
-0.6%
$8.25
+23.3%
+199.1%$2.06B$2.39B-11.957,700Short Interest ↑
Gap Down
INDV
Indivior
3.6207 of 5 stars
$17.05
-0.2%
$36.00
+111.1%
N/A$2.35B$1.09B1,705.001,164Short Interest ↓
News Coverage
Positive News
Gap Down
AMPH
Amphastar Pharmaceuticals
4.9799 of 5 stars
$41.91
-2.7%
$66.00
+57.5%
-4.9%$2.05B$644.40M14.501,761Short Interest ↓
Analyst Revision
Positive News
ARVN
Arvinas
2.4509 of 5 stars
$34.65
+4.2%
$61.13
+76.4%
+54.7%$2.37B$78.50M-5.84445Positive News
RCKT
Rocket Pharmaceuticals
3.846 of 5 stars
$22.33
-2.2%
$52.13
+133.4%
-1.2%$2.03BN/A-7.78268
BHC
Bausch Health Companies
4.0892 of 5 stars
$6.55
+0.6%
$11.33
+73.2%
-23.8%$2.40B$8.76B-5.2820,270Short Interest ↓
Analyst Revision
ZLAB
Zai Lab
2.4401 of 5 stars
$20.01
-4.0%
$64.22
+221.0%
-42.2%$1.99B$266.72M-5.732,175Short Interest ↓
Gap Down

Related Companies and Tools

This page (NASDAQ:DCPH) was last updated on 5/29/2024 by MarketBeat.com Staff

From Our Partners